Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Zdiagnozowana ostra białaczka szpikowa lub mieszana w remisji, lub zespół mielodysplastyczny wymagający przeszczepu.
- •Planowane łagodne przygotowanie do przeszczepu komórek macierzystych.
- •Znaleziony dawca (krewny lub niespokrewniony), który jest zgodny w kluczowych parametrach immunologicznych.
- •Prawidłowa praca nerek (nie wskazująca na znaczące problemy).
✗ Disqualifies
- •Pacjenci, którzy wcześniej przeszli przeszczep komórek macierzystych.
- •Obecnie przyjmujący leki osłabiające odporność (z wyjątkiem niskich dawek sterydów).
- •Planowane podawanie dodatkowych limfocytów od dawcy po przeszczepie.
- •Ogólny stan zdrowia uniemożliwiający uczestnictwo w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
UCLA Department of Medicine
Los Angeles, United States
Moffitt Cancer Center
Tampa, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, United States
Weill Cornell Medicine - New York Presbyterian Hospital
New York, United States
Oregon Health and Science University
Portland, United States
Vanderbilt University, Ingram Cancer Center
Nashville, United States
Trial contact
Chief Medical Officer
Medical Director
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.